MAPT and Alzheimer disease: APOE4 carriers and CI participants were more likely to be positive for AD pathology (tau/Aβ42, p < 0.05), and to have lower Aβ42/40 and higher p-tau than APOE4 non-carriers and CN participants (p < 0.01) (Additional file 1: Table S4).